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With cannabis use and policy evolving internationally, drug-impaired driving has 
become an increasingly relevant policy issue. This briefing aims to provide those 
concerned with policy developments in the field of cannabis with a brief overview of 
current knowledge and the latest developments in the area of driving.
The following topics are covered:
 I Contents
Cannabis and driving I Questions and answers for policymaking
4
Third international symposium on drug-impaired driving
This joint policy briefing draws on the evidence presented at the Third 
international symposium on drug-impaired driving, which took place on 23 
October 2017 in Lisbon. The symposium was a collaborative effort between 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the 
Canadian Centre on Substance Use and Addiction (CCSA), the US National 
Institute on Drug Abuse (NIDA) International Program and the New Zealand 
Drug Foundation. More than 100 participants attended the high-level event, 
which brought together researchers, practitioners and policy experts from over 
30 countries. All presentations and further information can be found on the 
conference website:  
http://www.emcdda.europa.eu/meetings/2017/3rd-symposium-drug-
impaired-driving_en
Terminology
Cannabis-impaired driving occurs when a person drives a motor vehicle when 
their ability to do so is impaired by the cognitive or psychomotor effects of 
tetrahydrocannabinol (THC) in cannabis.
A cannabis-positive driver is someone who drives a motor vehicle with 
detectable levels of THC in their blood, oral fluid or urine (depending on 
jurisdiction). Their driving may not necessarily be impaired by cannabis, for 
example if the THC level reflects cannabis use that occurred in the past but is 
still detectable.
Driving under the influence of cannabis, depending on the jurisdiction, may 
refer to a driver who has: a measured reduction in cognitive or psychomotor 
skills; more than a defined level of THC in the blood, oral fluid or urine, or any 
trace of THC in the blood, oral fluid or urine.
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Challenges for regulatory models
l  Why is cannabis use a road safety issue?
Consumption of cannabis affects cognitive and 
psychomotor performance in ways that can impair driving 
(Verstraete and Legrand, 2014; Hall et al., 2016). Cannabis 
contains a variety of cannabinoids, the most important 
being tetrahydrocannabinol (THC) and cannabidiol (CBD), 
which have very different effects on the brain. The relative 
amounts of these and other cannabinoids in cannabis 
plants and cannabis products vary widely. The THC in 
cannabis provides the predominant psychoactive effects 
and is considered to be mainly responsible for the 
impairment of function that affects driving ability.
Cannabis is a widely used substance. Within the general 
population, young adults have the highest rates of 
cannabis use (Canadian Centre on Substance Use and 
Addiction, 2017; EMCDDA, 2017) and are the age group at 
highest risk of motor vehicle crashes in the European 
Union (EMCDDA, 2012), Canada (Beirness and Porath, 
2017), the United States (Substance Abuse and Mental 
Health Services Administration, 2017) and Oceania 
(Australian Institute of Health and Welfare, 2017).
The recreational use of cannabis has been legalised in nine 
states in the United States and in Uruguay (as of 
April 2018) and the Canadian government plans to legalise 
it in 2018. These developments have heightened concerns 
about cannabis and driving, for two broad reasons. First, 
they mean that, in these jurisdictions, cannabis use will no 
longer be illegal in itself, so laws on driving after 
consuming cannabis might become much more like those 
for alcohol. Second, if cannabis legalisation increases the 
number of individuals in the population who use the drug, 
then the number of people who drive after using cannabis 
may also increase. The extent to which such an increase 
actually occurs is not clear (see question ‘Has cannabis 
legislation increased the number of cannabis-impaired 
drivers?’ on page 11). Evaluation of the impact of 
legalisation on both the extent of driving under the 
influence of cannabis and the impact on road traffic 
accidents and associated injuries is therefore important.
l  What is the extent of cannabis-impaired/positive driving in different countries?
Information on the extent of cannabis-impaired or 
cannabis-positive driving is collected in a variety of ways, 
which makes comparison difficult. It can be estimated 
using:
 ■ roadside surveys that (a) ask drivers about their 
cannabis and other drug use and (b) request biological 
samples to test for recent cannabis use;
 ■ general population surveys that ask individuals who use 
cannabis how often they drive after using cannabis.
The first of these methods is considered more robust than 
the second, which relies on self-reporting of a socially 
undesirable behaviour and is therefore likely to be subject 
to under-reporting.
It is difficult to compare the scale of driving under the 
influence of cannabis in different countries because the 
studies performed to date have used different methods 
(EMCDDA, 2014). For example, variations in the times of 
day studied, groups of drivers tested or cut-off levels for 
‘positive tests’ can lead to different results. A standardised 
survey in 13 countries in the European Union in 2007–
2009 found THC in 1.3 % of a sample of the general driving 
population, although in individual countries the results 
ranged from 0 to 6 % (EMCDDA, 2014). The US National 
Highway Traffic Safety Administration (NHTSA) National 
Roadside Survey of Alcohol and Drug Use by Drivers in 
2013–2014, using different methods, found that 12.6 % of 
weekend night-time drivers tested positive for THC.
Few surveys have been repeated to assess if these 
numbers are changing. In the US, the NHTSA roadside 
surveys have been conducted since 1973, but only the 
surveys in 2007 and 2013-2014 tested oral fluid and blood 
for the presence of drugs in samples of drivers. The 
prevalence of THC increased from 5.6 % in 2007 to 12.6 % 
in 2013-2014 (Berning et al., 2015). A recent study in 
Portugal found that the concentrations of THC found in 
blood samples taken from drivers increased between 2011 
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and 2013 but then remained fairly stable to 2015, with 
between 3 % and 4 % of drivers tested having THC 
concentrations of 10 ng/ml or more and about 30 % having 
concentrations of 3 ng/ml or above (Diaz, 2017) (see 
question ‘What levels of THC in blood indicate 
impairment?’ on page 9 for more information).
l  What are the risks associated with cannabis-impaired driving?
Cannabis use impairs skills related to driving in laboratory 
settings, as well as performance in driving simulators and 
in on-road driving studies (Compton, 2017b) but there is 
uncertainty about how these changes translate into crash 
risk (Compton, 2017a).
Assessing the risks of cannabis-impaired driving is further 
complicated by the fact that a number of factors can have 
an impact on whether a particular level of cannabis 
consumption will be associated with impairment of driving 
skills. These include the method of consumption 
(inhalation or ingestion; see question ‘Do edible and 
smoked cannabis products affect drivers in the same 
way?’ on page 7), whether the user is an infrequent or 
habitual user, and whether or not cannabis is used 
together with other substances, such as alcohol (Wolff & 
Johnston, 2014).
The impact of cannabis use on driving has been examined 
by a variety of different types of research. These have 
included:
 ■ laboratory studies of the effects of cannabis on skills 
relevant to driving;
 ■ studies of the effects of cannabis on driving 
performance in driving simulators;
 ■ studies of the effects of cannabis use on real on-road 
driving, usually on closed courses;
 ■ epidemiological studies of markers of cannabis use 
(usually the presence of THC) among injured and fatally 
injured drivers involved in road traffic accidents;
 ■ meta-analyses of the individual epidemiological 
studies.
Epidemiological studies of people seriously injured or 
fatally injured in road traffic accidents measure 
concentrations of THC (or its metabolites) in blood and 
urine (EMCDDA, 2014). These use one of two main 
approaches. Case-control studies compare the levels of 
THC or its metabolites in drivers fatally or seriously injured 
with levels in controls (usually drivers of a similar age who 
have not been involved in accidents). Culpability studies 
examine the association between the presence of THC 
and other drugs and an expert assessment of whether the 
driver was responsible for the crash (a judgement that is 
made without knowing whether the driver had used 
alcohol or drugs).
Cannabis is the illicit drug most often detected in drivers 
who have been injured or fatally injured in North America, 
Europe and Oceania (EMCDDA, 2012). This is not 
surprising, since cannabis is the most commonly used 
illicit drug.
However, a major challenge in interpreting the case-control 
and culpability studies is that the presence of THC in blood 
or urine (measured some hours after a crash) does not 
necessarily mean that the driver was impaired by cannabis 
at the time of the crash (Beirness, 2017; Compton, 2017a) 
(see questions ‘How useful are biological tests of THC in 
oral fluid and blood?’ and ‘What levels of THC in blood 
indicate impairment?’ on pages 8 and 9). It only 
indicates that cannabis was used in the recent past by 
someone who uses cannabis occasionally, or longer ago if 
the person uses cannabis regularly.
Meta-analyses of these epidemiological studies (Asbridge 
et al., 2012; Liet et al., 2012; Rogeberg and Elvik, 2016) 
have indicated that cannabis use is associated with 
a modest increase in the risk of a crash. It is estimated that 
drivers who have recently used cannabis are on average 
1.5 to 2 times more likely to be involved in a car crash 
(EMCDDA, 2012). Some researchers (Gjerde and Morland, 
2016) argue that this may be an underestimate because of 
the often quite long delay between the crash and the 
taking of the blood sample (see question ‘How useful are 
biological tests of THC in oral fluid and blood?’ on 
page 8). The increased risk of an accident is less for 
cannabis-impaired than for alcohol-impaired drivers 
(Beirness, 2017; Compton, 2017a). A blood alcohol 
concentration (BAC) of between 0.08 % and 0.12 %, for 
example, increases the risk of an accident by 5 to 30 times 
(EMCDDA, 2012).
However, the results of the research on the risks 
associated with cannabis and driving need to be 
interpreted with caution for the following reasons:
1. The modest effects of cannabis use on behaviour and 
coordination in the laboratory might not be relevant to 
driving on the road.
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2. Tests of injured and killed drivers may underestimate 
the risk, since they detect blood THC concentrations at 
the time of the test and not at the time of the crash, 
which may have been 1 to 2 hours earlier.
3. The presence of low THC concentrations in blood does 
not automatically imply recent cannabis use but may 
also be a result of past use in someone who uses 
cannabis regularly and may be unimpaired.
4. It is usually not possible to be certain if the presence of 
THC indicates that it was the main reason for the crash.
l  Do edible and smoked cannabis products affect drivers in the same way?
‘Edible cannabis products’ come in the form of cookies, 
confectionery and drinks that can contain substantial 
amounts of THC. In general, the effects of oral cannabis 
consumption are less predictable, the onset is slower and 
the effects last longer. In the US, there is a growing use of 
edible cannabis products for medical or recreational use, 
in part to avoid the health risks associated with the 
inhalation of cannabis smoke (McInnis and Plecas, 2016).
Laboratory studies have found important differences 
between the pharmacology of oral and smoked cannabis 
(Huestis, 2005). Smoking cannabis leads to a rapid rise in 
blood THC concentration and the associated onset of 
acute effects. Blood THC concentrations generally fall 
rapidly after smoking ceases, by 80 % within half an hour, 
although the effects can persist for four to six hours after 
use (Wolff et al., 2013). However, in daily or near daily 
users, THC accumulates in fatty tissue and then seeps 
back into the bloodstream, resulting in some THC being 
present in the blood over long periods.
In contrast, when cannabis is consumed orally, absorption 
of THC into the blood is much slower and less predictable. 
Behavioural effects set in with a delay of 30–90 minutes, 
reach their maximum after two to three hours and last for 
about 4–12 hours, depending on the dose (Wolff et al., 
2013). When it is taken orally, less THC gets into the 
bloodstream, so the maximum concentration of THC in 
blood is lower than when cannabis is smoked. These lower 
concentrations, however, can persist much longer after oral 
use than after smoking cannabis (Vandrey et al., 2014).
A recent study among occasional and frequent cannabis 
smokers using common impairment tests (one-leg stand, 
walk and turn, etc.) found performance was significantly 
impaired after cannabis was consumed orally (Newmeyer 
et al., 2017). Again, it suggested that impairment is more 
prolonged and occurs later after cannabis is eaten than 
after it is inhaled.
The effects on driving ability of the variety of new cannabis 
products, such as those with high THC content (65-75 %) 
now appearing on the legal market in the US, are not known 
(Raber et al., 2015). As the range of cannabis products 
grows, it will be important to study how they are used, how 
they are metabolised and how they affect driving.
l  What are the regulatory options for addressing cannabis-impaired driving?
The policies to reduce cannabis-impaired driving have 
often been modelled on those that have proven effective in 
reducing alcohol-impaired driving over the past 40 years 
(Compton, 2017a). Therefore, they have included:
 ■ roadside testing of probable cannabis-related 
impairment, using either (a) a test of behavioural 
impairment or (b) an oral fluid test administered by 
a police officer;
 ■ for drivers who fail the roadside test (because the oral 
fluid test is positive or the police officer assesses the 
driver to be impaired), confirmation of the commission 
of an offence by a test to measure blood THC 
concentration;
 ■ defining drug-impaired driving by law, based on 
a specified level of THC in the blood or, occasionally, in 
oral fluid (see question ‘What levels of THC in blood 
indicate impairment?’ on page 9).
Some jurisdictions have taken a zero-tolerance approach 
because of the illicit nature of the drug and set a low 
cut-off level in blood. This approach does not rely on the 
need to measure behavioural impairment.
People convicted of drug-driving offences usually lose 
their licence for some period or pay a fine or both. In some 
jurisdictions a prison sentence might be imposed for 
a higher range blood THC level, or on people with prior 
drug driving offences or those who have caused injury or 
death by such driving.
For the reasons examined in the next two questions, there 
are challenges in using the alcohol control approach to 
reduce cannabis-impaired driving.
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Drug screening, testing and detection
l  How useful are behavioural assessments of cannabis-related impairment?
In some jurisdictions, police officers can assess signs of 
behavioural impairment if they suspect someone is driving 
under the influence of drugs (Beirness, 2017; Beirness and 
Porath, 2017). This assessment can be done by sobriety 
assessments at the roadside. Drivers who fail the roadside 
behavioural test can be given confirmatory tests, either at 
the roadside or in a police station or medical setting 
(Beirness and Porath, 2017).
The most common roadside test of behavioural impairment 
in the US is the Standardized Field Sobriety Test (SFST). 
The SFST was designed to detect alcohol-related 
impairment based on known symptoms of alcohol 
consumption and impairment. As symptoms of cannabis 
impairment are different, it is not as sensitive to cannabis-
related driving impairment; one study found the SFST 
identified only 41 % of cases of cannabis impairment 
correctly (Beirness and Porath, 2017; Compton, 2017a).
More detailed tests of behavioural impairment can be 
performed by specially trained police officers (usually in 
a police station). The Drug Evaluation and Classification 
(DEC) programme consists of coordination and divided 
attention tests; eye examinations; measurements of blood 
pressure and temperature; observations; and an interview. 
The DEC programme aims to determine if the suspect is 
impaired, whether this is due to drugs and which category 
(or categories) of drugs are most likely to be responsible. 
The DEC evaluation can take up to an hour. The DEC 
programme performs much better than roadside sobriety 
testing in detecting cannabis-related impairment, and 
trained officers are able to identify the class of drugs 
responsible for the impairment with an accuracy of 95 % 
(Beirness and Porath, 2017).
It may be difficult to implement the DEC on a large scale 
because it takes considerable time and money to train 
specialised officers to perform it and it is time-consuming 
for police officers to wait for a trained officer to perform 
a DEC. This is one reason that oral fluid screening for drugs 
is preferred in a number of countries.
l  How useful are biological tests of THC in oral fluid and blood?
A roadside oral fluid test can identify drivers who have 
recently used cannabis and who may potentially be 
cannabis impaired. Drivers who screen positive in the oral 
fluid test are usually required to provide a blood sample for 
testing of THC concentration. If their blood THC 
concentration exceeds a statutory level, they are defined 
as cannabis-impaired or driving under the influence. The 
threshold selected will have a significant impact on the 
numbers of people who will be prosecuted. A study of 
drivers found to be THC positive in Portugal showed that, if 
the concentration was set at 1 ng/ml, 67 % of drivers 
would have been prosecuted but, using a concentration of 
3 ng/ml, only 26 % would have been prosecuted 
(Diaz, 2017).
There are challenges with using biological tests for THC to 
assess driving impairment. First, the outcomes of oral fluid 
screening and those from blood tests quite often do not 
match. In the United Kingdom, in cases where oral fluid 
screens were positive, 32 % of blood tests were found to 
be at or below the legal limit (Castillo, 2017).
Second, the amount of THC in blood or oral fluid is not as 
strongly related to driver impairment as BAC is to alcohol-
impaired driving. The proportion of individuals showing 
impairment in several performance domains progressively 
increases as blood THC concentrations increase, but the 
rate of increase is quite low and the first indications of 
impairment have been demonstrated at THC 
concentrations between 2 and 5 ng/ml (Ramaekers et 
al., 2006).
Meta-analyses combining the data from a large number of 
studies have found that, in general, the higher the 
estimated concentration of THC in blood, the greater the 
driving impairment, but that frequent users of herbal 
cannabis show less impairment than infrequent users 
(unless used in conjunction with alcohol) at the same 
dose. Studies to date indicate that a blood concentration 
of about 3.7 ng/ml THC impairs drivers to a level equivalent 
to a BAC of 0.05% (0.5 mg/ml) (Berghaus et al., 2010).
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In addition, there is a very sharp initial rise in blood THC 
concentration when a cannabis cigarette is smoked, 
followed by a rapid fall (Compton, 2017a) (see question ‘Do 
edible and smoked cannabis products affect drivers in the 
same way?’ on page 7). The rapid decline in blood THC 
level occurs while the psychomotor and cognitive 
impairments are most marked, namely starting 90 minutes 
after use and lasting for 2 to 3 hours.
However, THC can also be detected in blood at very low 
concentrations long after any cannabis-related driving 
impairment has disappeared, particularly in the case of 
frequent cannabis users. Blood concentrations of THC are 
also affected by the delay between a roadside oral fluid 
test and a confirmatory blood test (often up to several 
hours) (Compton, 2017a; Ramaekers, 2017). For example, 
in studies in the US, the typical time before blood is taken 
for testing following arrest for driving under the influence 
of drugs or being involved in a crash is 1.5 to 3 hours. In 
general, the longer the time between a roadside oral fluid 
test and a blood test, the lower the blood THC 
concentration.
It is perhaps for these reasons that a few jurisdictions, 
such as Spain, France, Cyprus and the Australian state of 
Victoria, have chosen to use oral fluid as the confirmatory 
test matrix and the result of the test as evidence for 
a conviction, following an initial screening test.
l  What levels of THC in blood indicate impairment?
As discussed above, there is no straightforward 
relationship between THC levels in the blood and 
impairment, but legal penalties are more likely to deter 
people from driving after using cannabis if there is 
a credible form of testing for impairment. Roadside oral 
fluid testing combined with a blood test and a specified 
level of THC that is taken to indicate impairment, is 
practicable for the police to enforce. The THC 
concentration specified in law to define impairment or 
driving under the influence differs between countries.
In Australia and many European Union countries, the THC 
concentration used to define a cannabis-related driving 
offence has been set between 1 and 2 ng/ml of THC in 
blood (ng/ml) (see Table 1). In a few European countries 
penalties increase with increasing blood concentrations of 
THC (e.g. the Netherlands and Norway) (see Hughes, 2017; 
Ramaekers, 2017; Vindenes, 2017). In some US states in 
which recreational cannabis use is legal, a concentration 
of 5 ng/ml has been defined as evidence of impairment 
(Compton, 2017a).
Expert committees in different countries have 
recommended concentrations of 5 ng/ml (UK) based on 
road traffic risk (Wolff et al., 2013) or 7 ng/ml (Ramaekers 
et al., 2004). However, THC concentrations used to define 
offence thresholds tend to be lower than those 
recommended by expert committees. For example, a level 
of 2 ng/ml was adopted in the United Kingdom, using the 
lower limit of quantification, taking into account potential 
accidental exposure. This reflects a zero-tolerance 
approach to driving under the influence of cannabis rather 
than a link to impairment.
The 5 ng/ml concentration adopted in some US states has 
also been criticised. It has been characterised as not 
sufficiently evidence-based and its adoption could lead to 
substantial numbers of drivers identified as behaviourally 
impaired by police officers being ‘exonerated’ by the blood 
test (Compton, 2017b). In Colorado, the 5 ng/ml 
concentration adopted was the concentration at which 
jurors could infer impairment, rather than being 
a strict limit.
In Portugal, where no threshold limit is provided for in law, 
a study comparing THC concentration ranges detected in 
drivers and the rate of prosecution for cannabis-impaired 
driving showed similar rates for all concentration ranges 
(Diaz, 2017).
TABLE 1
Legal cut-off concentrations for blood levels of THC in 
some European countries
THC
(ng/ml)
Country
1 Belgium
Denmark
Ireland
Luxembourg
Netherlands (if other drugs are present)
1.3 Norway (*)
2 Czech Republic
United Kingdom
3 Netherlands (if THC only is detected)
Norway (*)
9 Norway (*)
(*) In Norway, the severity of the penalty is increased according to the level 
of THC detected.
Source: Hughes, 2017
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Part 3
Preventing cannabis-impaired driving
l  How can the public and drivers be educated to discourage cannabis-impaired driving?
Individuals who use cannabis need to be educated about 
the risks of driving and discouraged from driving under the 
influence of cannabis (Beirness, 2017; EMCDDA, 2012). 
However, such education alone is unlikely to be sufficient 
to reduce cannabis-impaired driving because similar 
approaches have not reduced alcohol-impaired driving 
(EMCDDA, 2012). The programmes that have successfully 
reduced alcohol-impaired driving have combined 
education about the risks of driving after drinking with 
rigorous enforcement of laws that prohibit alcohol-
impaired driving (defined by specified BAC levels).
A major challenge in discouraging driving after using 
cannabis is countering misconceptions among young 
people about the effects that cannabis use has on driving 
(Beirness and Porath, 2017; Grondel, 2017). Young people 
who use cannabis in Canada, the US and elsewhere, often 
believe that they can drive better after using cannabis 
because they take greater care. They might also think that, 
because cannabis produces less impairment and risk 
taking than alcohol, it is safe to drive after using cannabis; 
that is, they may confuse lower risk, compared with alcohol 
use, with no risk. They may also believe that they are at low 
risk of being caught if they drive after using cannabis 
(Beirness and Porath, 2017; Castillo, 2017; McKiernan and 
Fleming, 2017). This supports the idea that, to be effective, 
programmes will need to combine well-designed 
preventative education programmes about the risks 
associated with cannabis use and driving with 
enforcement of laws relating to driving under the influence 
of cannabis.
l  What sanctions would be most effective for cannabis-impaired drivers?
A wide range of possible penalties proportionate to the 
threat to road safety may be seen as more credible and 
coherent as a road safety policy, than applying the same 
penalty for all offences. For example, more severe 
penalties might be applied to people who drive with higher 
concentrations of THC in their blood (as indicators of 
cannabis-impaired driving), repeatedly engage in 
cannabis-impaired driving and use multiple drugs 
(including alcohol), as is the case in France, the 
Netherlands and Norway (Hughes, 2017; Ramaekers, 2017; 
Vindenes, 2017). Similarly, consistency with legislation on 
alcohol-impaired driving can also be viewed as important. 
In Norway, the concentrations of THC specified for 
different penalty levels were identified on the basis of 
comparability with penalties for alcohol-impaired driving 
(Vindenes, 2017).
In research about alcohol-impaired driving, rehabilitation 
courses show promising results, so referral for drug 
counselling or treatment can also be considered; Colorado 
has a treatment track for cannabis-impaired drivers 
(Davis, 2017).
l  Does biological testing for cannabis encourage use of alternative substances?
Testing for THC (e.g. using oral fluid testing at the roadside) 
could possibly encourage individuals who use cannabis to 
use drugs with similar effects that will not be detected by 
these tests (Loeffler et al., 2016). These drugs could 
include potent synthetic cannabinoids (a diverse range of 
substances that act on the same receptor systems in the 
brain as THC and are often sold as ‘herbal smoking 
mixtures’ with brand names such as Spice and K2), which 
have appeared in drug markets in recent years (EMCDDA, 
2015). More research is needed to assess the prevalence 
of synthetic cannabinoid use among drivers and the 
severity of the impairment they produce. The former could 
be achieved by testing for synthetic cannabinoids in 
biological samples that have been tested for cannabis and 
found not to contain THC. The latter would require 
specialist, sophisticated laboratory equipment and driving 
simulator and epidemiological studies. In response to 
concerns about increasing use of synthetic cannabinoids, 
tests for a range of synthetic cannabinoids are being 
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developed, although few are available for routine testing. 
A major research challenge, however, is the diversity within 
this group of substances.
l  How should the law treat people who use cannabis for medical reasons and drive?
In the US and Canada, several jurisdictions permit smoking 
cannabis for medical reasons. In the European Union, 
smoking is not permitted, but in the last few years several 
countries have permitted vaporising or infusion of 
cannabis for a limited number of conditions. Prescribing 
practices are not standardised and range from being 
loosely to tightly controlled. The increased availability of 
cannabis and THC for medical use could increase the 
number of people who are detected driving with THC blood 
concentrations in excess of 1-2 ng/ml. The issue has 
parallels with concerns about the potential effects on 
driving of other medicines, such as sedatives and opioids.
In some countries, people who drive after using cannabis 
for medical reasons or approved pharmaceutical medical 
cannabis products are exempted from prosecution for 
cannabis-impaired driving if they can show that they were 
prescribed the substance and were not impaired. This is 
the policy in Ireland (Maguire, 2017), Norway (Vindenes, 
2017) and the United Kingdom (Wolff, 2017). The main 
argument for granting an exemption is that it will enable 
patients who use cannabinoids for medical purposes to 
live a more normal life. The fact that regular use of 
cannabis could result in low levels of THC in the blood for 
long periods following use without apparent impairment 
may be a consideration. The counterargument is that use 
of prescribed cannabis can still cause impaired driving and 
threaten road safety.
l  Has cannabis legalisation increased the number of cannabis-impaired drivers?
There is a concern that decriminalisation and legalisation 
of cannabis for recreational use might increase the 
prevalence of cannabis use and, by extension, its use 
among drivers. Legalisation may, for example, make 
cannabis easier to access, reduce its price and social 
disapproval of its use and enable individuals to use 
cannabis without fear of arrest (Hall and Lynskey, 2016). 
There is conflicting evidence from population surveys in 
the US on whether use has increased in states that have 
adopted more liberal medical cannabis laws or have 
legalised recreational cannabis use (Lynskey and 
Hall, 2016).
Since Washington state and Colorado legalised 
recreational cannabis use by adults (Davis, 2017; Grondel, 
2017), there has been an increase in the number of drivers 
detected driving after using cannabis. However, there has 
also been an increase in rates of testing drivers for recent 
cannabis use because drug driving laws have been 
enforced more stringently. This increase makes it difficult 
to interpret these findings.
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Part 4
Future perspectives for research 
and monitoring
l  How can knowledge of the number of cannabis-using drivers on the roads, and their role in accidents, be improved?
Data need to be collected in standardised ways to enable 
cross-national comparisons of the rates of cannabis-
impaired driving or driving under the influence of cannabis. 
Ideally, this collection would include regular roadside 
surveys coupled with the testing of biological samples to 
monitor trends in cannabis use and driving (Wolff et al., 
2013; Wolff, 2017; Compton, 2017a). It would also include 
monitoring the prevalence of cannabis and other drugs in 
those involved in road fatalities and injuries, using 
standardised analytical methods (EMCDDA, 2012) and 
data collection techniques.
Jurisdictions that have legalised cannabis use (or are 
considering doing so) could put in place systems for 
monitoring cannabis-impaired driving (before and) after 
legalisation. These systems might include regular roadside 
drug testing and the use of standardised approaches to 
analysing biological samples for evidence of recent 
cannabis use in drivers who have been killed or seriously 
injured in car crashes (Compton, 2017a).
Larger and better controlled studies are needed to determine 
precisely the contribution that cannabis use makes to road 
crash fatalities and serious injuries (Compton, 2017a). There 
are few studies of cannabis-impaired driving that are as large 
and as well designed as those that have been carried out on 
alcohol-impaired driving.
There is a need for more basic research on the 
pharmacology of cannabis to provide biological and 
behavioural measures of cannabis-impaired driving that 
can be used to identify and deter drug-impaired driving. 
For example, the use of blood spots (from finger pricks) is 
a potentially innovative approach that could allow the 
measurement of blood THC closer to the time of an 
accident or detection by police than is currently possible 
(Sadler et al., 2017), but as yet this testing has not been 
sufficiently developed to be put into routine use (Wolff et 
al., 2017). Its feasibility and validity need to be investigated 
(Quraishi et al., 2017) alongside other potential methods, 
such as roadside testing using latent fingerprints and 
detection in exhaled breath.
l  How can policies addressing cannabis-impaired driving be evaluated?
We need better evaluations of the effectiveness of policies 
to deter cannabis-impaired driving (Flieger, 2017; Hughes, 
2017; Wells, 2017). These policies have been in place in 
Australia for 17 years but their impacts have been poorly 
evaluated (Davey et al., 2017). Similar policies have 
recently been introduced in the EU and US. Studies 
evaluating them have been limited to describing 
enforcement activities rather than evaluating their impacts 
on the prevalence of cannabis-impaired driving, injuries or 
fatalities (e.g., Castillo, 2017; Diaz, 2017; Vindenes, 2017; 
Wolff, 2017).
These evaluations have reported on the number of drivers 
tested for different types of drug use; the number who 
tested positive; and the number convicted of drug-
impaired driving (e.g., Castillo, 2017; Davey et al., 2017; 
Diaz, 2017; Vindenes, 2017; Wolff, 2017). Increased drug 
testing could produce a public health impact on cannabis-
impaired driving, but this might not be sufficient.
Future evaluations need to examine trends in road 
fatalities and injuries in which alcohol, cannabis and other 
drugs are detected post mortem; changes in public 
attitudes towards the acceptability of driving after using 
cannabis; and changes in young adults’ perceptions of the 
risks of being detected by the police if they drive after 
using cannabis (Hughes, 2017).
There is also a need to evaluate the effects of education 
and prevention programmes. This evaluation should 
include research on how to convey information about the 
risks of driving after using cannabis and how best to 
discourage people from engaging in this behaviour.
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Evaluations are needed of the cost-effectiveness of drug 
testing, much like economic evaluations of policies to 
reduce driving under the influence of alcohol. These need 
to consider the opportunity costs of enforcing laws against 
cannabis-impaired driving instead of those against alcohol-
impaired driving. Alcohol-impaired driving remains a much 
larger road safety and public health problem than 
cannabis-impaired driving (despite success in reducing its 
prevalence) because alcohol is a more serious cause of 
driver impairment and many more drivers drink alcohol 
than use cannabis (EMCDDA, 2012).
Most of the research on the prevalence of cannabis-
impaired driving and most evaluations of policies to reduce 
cannabis-impaired driving have been done in high- and 
middle-income countries, such as the Member States of 
the EU, the US and Australia. There has been very little 
evaluation of how useful these policies may be in 
discouraging cannabis-impaired driving in low- and 
middle-income countries in which this behaviour might 
also be common. Research is needed in these countries to 
develop practicable ways of enforcing laws against 
drug-impaired driving (Khayesi, 2017).
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